Omontys
(Peginesatide)ApprovedPeptide
TakedaOmontys is a peptide that works as a Erythropoietin Receptor Agonist; Erythropoietin Receptor Agonist.[2] It is being used across 1 indication, with its most advanced program in Approved.[1]
Omontys is one of 37 small molecule programs targeting Anemia (phenotype). It is currently in Approved.
1
Indications
19
Total Trials
0
Active Trials
36
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Anemia (phenotype)
#DrugCompanyPhaseTrials
1Avandia
Jazz PharmaceuticalsApproved
Actos
TakedaApproved
Exjade
NovartisApproved
Niacor
AbbVieApproved
Golytely
BayerApproved
Crestor
AstraZenecaApproved
Lopid
PfizerApproved
Avelox
BayerApproved
Ansaid
PPharmacia and Upjohn
Approved
Miochol
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anemia9 trials
Show 6 more trials
Chronic Kidney Disease6 trials
Show 3 more trials
Chemotherapy2 trials
Intravenous1 trial
Regulatory
FDA Approval Timeline[4]
Mar 27, 2012
OMONTYS
NDA NDA202799
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Peginesatide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]